chartexchange

HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results

GlobeNewswire Inc. | Nov 16, 2026 8:15 AM EST

MIRAMAR, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and nine months ended September 30, 2026.

Read original article